ReviewFrontiers in immunology2022
The role of
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 153 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
153 citing papers in PubMed, 3 syntheses or guidelines pooled it, 193 citations in OpenAlex.
- IBD-related inflammatory memory and colorectal cancer: epigenetic mechanisms and microbiome interventions.Frontiers in immunology · 2026Pooled it
- The role ofFrontiers in medicine · 2025Pooled it
- The Impact of Cesarean Section Delivery on Intestinal Microbiota: Mechanisms, Consequences, and Perspectives-A Systematic Review.International journal of molecular sciences · 2024Pooled it
- A bile acid-GPBAR1 network supports anti-inflammatory and anti-fibrotic benefits of probiotics in colitis.Gut microbes · 2026Article
- Goat and cow milk merits distinct nutritional and functional properties based on simulated gastrointestinal digestion of infant.Food chemistry: X · 2026Article
- Akkermansia muciniphila WW001 protects against DSS-induced colitis by restoring intestinal barrier integrity and modulating inflammatory responses.Folia microbiologica · 2026Article
- Functional Gut Microbiota Alterations in Patients with Inflammatory Bowel Disease Receiving Long-Term Biologic Therapy: A Pilot Comparative Study.Journal of clinical medicine · 2026Article
- Gut microbiome dysbiosis, short-chain fatty acid depletion and implications for neuroinflammation in atypical parkinsonian syndromes - a systematic review of patient cohorts.Journal of Parkinson's disease · 2026Review
- Virobiome-mediated regulation of microbiota-gut-brain axis signaling and neuroimmune homeostasis.Cell communication and signaling : CCS · 2026Review
- Haikun Shenxi Capsule Ameliorates Renal Fibrosis by Modulating Gut Microbiota and Metabolism.Current medical science · 2026Article
- Article
- Review
- Few-shot learning-driven discovery of Lutein suppresses Th1-mediated inflammation via glucose metabolism.Acta pharmacologica Sinica · 2026Article
- Investigation of the Effect of Akkermansia muciniphila Muc T (ATCC BAA-835) on TLR4/NF-Kappa B/NLRP2 Signaling Pathway and Intestinal Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome in Rats.Probiotics and antimicrobial proteins · 2026Article
- Arctic Fox-DerivedLife (Basel, Switzerland) · 2026Article
- Akkermansia muciniphila : A next-generation gut probiotic supporting neurorepair and functional recovery.Neural regeneration research · 2026Article
- From copper imbalance to immunometabolic remodeling: cuproptosis-related vulnerability and therapeutic hypotheses in autoimmune diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- SigMine and OPathDb: a literature-mining pipeline and database of potential opportunistic pathogens.Archives of microbiology · 2026Article
- Akkermansia muciniphila supplementation alters inflammatory profiles across diverse models of colitis.Scientific reports · 2026Article
- Identification of potential biomarkers for ulcerative colitis based on multidimensional data analysis and investigation of the mechanisms of therapeutic effects.BMC gastroenterology · 2026Article
93 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, is a chronic relapsing gastrointestinal inflammatory disease mediated by dysregulated immune responses to resident intestinal microbiota. Current conventional approaches including aminosalicylates, corticosteroids, immunosuppressive agents, and biological therapies are focused on reducing intestinal inflammation besides inducing and maintaining disease remission, and managing complications. However, these therapies are not curative and are associated with various limitations, such as drug resistance, low responsiveness and adverse events. Recent accumulated evidence has revealed the involvement of mucin-degrading bacterium
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.